In Asian patients with hepatitis C virus (HCV) infection, the genotype 6 infection contributes to an increased risk of hepatocellular carcinoma (HCC), particularly among those with liver cirrhosis, reports a multinational team of investigators.
Detection of circulating tumour cells (CTCs), circulating tumour DNA (ctDNA) and microRNA (miRNA) using blood samples (liquid biopsy) instead of cancer tissue proved useful in detecting progression and predicting prognosis of patients with bladder cancer, according to data presented at the recent 15th Urological Association of Asia Congress (UAA 2017) held in Hong Kong.
New drug applications approved by US FDA as of 1 - 15 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Capecitabine appears to provide additional survival benefit in triple-negative breast cancer patients treated with standard chemotherapy, significantly improving disease-free survival and overall survival but potentially increasing adverse events consistent with the drug’s known toxicity profile, according to a meta-analysis.
Young women with HER2-negative breast cancer had improved breast cancer-free interval (BCFI) rates following treatment with ovarian function suppression (OFS) in addition to tamoxifen or exemestane, according to a recent study.
Prostate biopsy using the multiparametric MRI/ultrasound fusion-guided (mpMRI/US) technique improves prostate cancer diagnosis and reduces the detection of clinically insignificant cancers, according to data presented the 15th Urological Association of Asia Congress (UAA 2017) held recently in Hong Kong.
Optimizing perioperative chemotherapy in bladder cancer (BC) presents a clinical challenge, as reflected in a debate at the 15th Urological Association of Asia Congress held in Hong Kong, which focused on the benefits and drawbacks of adjuvant chemotherapy (AC) after radical cystectomy (RC).
Practice-changing results from several clinical trials reported in the past 2 years have offered new effective treatment options for hormone-naïve prostate cancer (PC) patients, according to Dr Gerhardt Attard from the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK, who spoke at the 15th Urological Association of Asia Congress (UAA 2017) held recently in Hong Kong.
Brentuximab showed potential as an alternative front-line treatment for patients with Hodgkin lymphoma aged ≥ 60 years who cannot tolerate standard combination chemotherapy in a phase II, open-label study.
The connection between prediabetes, diabetes, and risk of hepatocellular carcinoma (HCC) in HBsAg and anti-HCV seronegative patients, as well as the association between fasting glucose and HCC were examined in this study.
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are superior to chemotherapy as first-line therapy for advanced non-small cell lung cancer (NSCLC) with positive EGFR gene mutations in terms of progression-free survival rates, says an expert.